Advertisement
Advertisement
BRNS
Barinthus Biotherapeutics plc - ADR
0.60
USDSponsored
+0.03
+6.02%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.58
-0.02
-2.67%
BRNS Earnings Reports
Positive Surprise Ratio
BRNS beat 14 of 21 last estimates.
67%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.29
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/+20.83%
Barinthus Biotherapeutics plc - ADR earnings per share and revenue
On Aug 05, 2026, BRNS reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.28 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.96% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.29 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
FAQ
What were Barinthus Biotherapeutics plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Barinthus Biotherapeutics plc - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Barinthus Biotherapeutics plc - ADR's Q2 2026 earnings?
The stock price moved up 0.96%, changed from $0.56 before the earnings release to $0.57 the day after.
When is Barinthus Biotherapeutics plc - ADR expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Barinthus Biotherapeutics plc - ADR's next earnings report?
Based on 4
analysts, Barinthus Biotherapeutics plc - ADR is expected to report EPS of -$0.29 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement